Journal of Cancer Research and Clinical Oncology

, Volume 139, Issue 10, pp 1771–1775

Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma

  • Wolfgang Lamm
  • Johannes Drach
  • Barbara Kiesewetter
  • Christoph C. Zielinksi
  • Marius E. Mayerhöfer
  • Leonhard Müllauer
  • Markus Raderer
Rapid Communication

DOI: 10.1007/s00432-013-1475-4

Cite this article as:
Lamm, W., Drach, J., Kiesewetter, B. et al. J Cancer Res Clin Oncol (2013) 139: 1771. doi:10.1007/s00432-013-1475-4

Abstract

Purpose

The management of patients with mantle cell lymphoma (MCL) not eligible for stem cell transplantation in relapse after receiving standard approaches remains challenging, and the search for active and tolerable regimens is still warranted.

Patients and methods

We have retrospectively analyzed activity of rituximab (375 mg/m2 i.v. day 1), Ara-C (1,000 mg i.v. total twice daily on day 2) and oxaliplatin (130 mg/m2 i.v. day 3) (R-ADOx) in 12 patients (median age 69 years) with relapsed MCL.

Results

Patients had been heavily pretreated (median 3 prior therapies, range 1–9) and had stage III/IV disease. Nine out of 12 patients responded (75 %, 4 CR, 5 PR). Median progression-free survival was 9.3 months, and overall survival has not been reached. Adverse events greater than grade II included anemia (17 %) and thrombocytopenia (33 %).

Conclusion

R-ADOx is active and well tolerated in heavily pretreated MCL patients.

Keywords

RituximabCytarabineOxaliplatinMantle cell lymphomaRelapse

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Wolfgang Lamm
    • 1
  • Johannes Drach
    • 1
  • Barbara Kiesewetter
    • 1
  • Christoph C. Zielinksi
    • 1
  • Marius E. Mayerhöfer
    • 2
  • Leonhard Müllauer
    • 3
  • Markus Raderer
    • 1
  1. 1.Clinical Division of Oncology, Department of Internal Medicine IMedical University of ViennaViennaAustria
  2. 2.Department of RadiologyMedical University of ViennaViennaAustria
  3. 3.Department of PathologyMedical University of ViennaViennaAustria